SEC filings
Regeneron Pharmaceuticals (REGN)
Recent filings Regeneron Pharmaceuticals made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000872589All filings on SEC.gov
10-QQuarterly report
Quarterly report
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.12 billion and net income of $1.95 billion, or $18.45 per diluted share, versus $3.75 billion and $1,460.0 million a year earlier. …
8-KCurrent report
Results of Operations and Financial Condition
Regeneron Pharmaceuticals reported third-quarter 2026 revenues of $5.1 billion, up 36% from a year earlier, with GAAP EPS of $18.45 and non-GAAP EPS of $20.07, and said it expanded its antibody collaboration with Sanofi through a $1.0…
8-KCurrent report
Entry into a Material Definitive Agreement; Results of Operations and Financial Condition …
Regeneron Pharmaceuticals and Sanofi entered a sixth amendment to their antibody license and collaboration agreement on October 1, 2026, under which the companies will co-develop and co-commercialize four new Regeneron-invented antibodies…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Regeneron Pharmaceuticals granted one-time performance share units (2026 PSUs) to CEO Leonard Schleifer and CSO George Yancopoulos effective September 24, 2026, replacing their annual equity awards through 2036 under a 10-year performance…
10-QQuarterly report
Quarterly report
Regeneron Pharmaceuticals reported second-quarter 2026 revenues of $4.29 billion, up from $3.68 billion a year earlier, while net income fell to $1.30 billion from $1.39 billion. …
8-KCurrent report
Results of Operations and Financial Condition
Regeneron Pharmaceuticals reported second-quarter 2026 revenues of $4.3 billion, up 17% year over year, with global Dupixent net sales up 38% to a new high of $6.0 billion and U.S. EYLEA HD net sales up 52% to $596 million. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Regeneron Pharmaceuticals in Readster
Add Regeneron Pharmaceuticals to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.